Novasoy and genistein inhibit endometrial cancer cell proliferation through disruption of the AKT/mTOR and MAPK signaling pathways.
Kim M. Malloy(University of North Carolina at Chapel Hill), Victoria Bae‐Jump(University of North Carolina at Chapel Hill), Yajie Yin(Parker Institute for Cancer Immunotherapy), Leslie H. Clark(University of North Carolina at Chapel Hill), Jiandong Wang(Beijing Obstetrics and Gynecology Hospital), Ziwei Fang(University of North Carolina at Chapel Hill), Weimin Kong(Capital Medical University), Wenchuan Sun(University of North Carolina at Chapel Hill), Chun Zhou(Guangdong Pharmaceutical University)
PubMed
January 1, 2018
Cited by 38
Related Papers
Up-Regulation of TWIST in Prostate Cancer and Its Implication as a Therapeutic Target
|Cancer Research|2005|467
CXCR4 Regulates Interneuron Migration in the Developing Neocortex
|Journal of Neuroscience|2003|455
Mechano-regulation of Peptide-MHC Class I Conformations Determines TCR Antigen Recognition
|Molecular Cell|2019|169
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer
|Cancer Medicine|2014|139
FRAX597, a Small Molecule Inhibitor of the p21-activated Kinases, Inhibits Tumorigenesis of Neurofibromatosis Type 2 (NF2)-associated Schwannomas
|Journal of Biological Chemistry|2013|134